Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy

References

• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030. PMID:26027431.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558–68. doi:10.1016/S1470-2045(16)30366-7. PMID:27622997.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17. doi:10.1056/NEJMoa1414428. PMID:25891304.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30. doi:10.1056/NEJMoa1412082. PMID:25399552.
   PubMed Web of Science ®Google Scholar
• Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84. doi:10.1016/S1470-2045(15)70076-8. PMID:25795410.
   PubMed Web of Science ®Google Scholar
• Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, Jiang J, et al. Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785–92. doi:10.1200/JCO.2015.66.1389. PMID:28068177.
   PubMed Web of Science ®Google Scholar
• Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016;17(7):943–55. doi:10.1016/S1470-2045(16)30126-7. PMID:27269740.
   PubMed Web of Science ®Google Scholar
• Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. CheckMate 025 randomized phase 3 study: Outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced Renal Cell Carcinoma. Eur Urol. 2017;72(6):962–71. doi:10.1016/j.eururo.2017.02.010.
   Web of Science ®Google Scholar
• Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, et al. Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–7. doi:10.1200/JCO.2014.59.0703. PMID:25452452.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER,et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. doi:10.1056/NEJMoa1510665. PMID:26406148.
   PubMed Web of Science ®Google Scholar
• Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol. 2017;35(34):3851–8. JCO2016721985. doi:10.1200/JCO.2016.72.1985. PMID:28678668
   PubMedGoogle Scholar
• Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–65. doi:10.1016/S1470-2045(15)70054-9. PMID:25704439.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Lopez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883–95. doi:10.1016/S1470-2045(16)30098-5. PMID:27269741.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(25):2969–79. doi:10.1200/JCO.2016.66.9861. PMID:27354481.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Brahmer J. Nivolumab in nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2016;374(5):493–4. PMID:26840144.
   PubMed Web of Science ®Google Scholar
• Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, et al. Nivolumab monotherapy for first-line treatment of advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(25):2980–7. doi:10.1200/JCO.2016.66.9929. PMID:27354485.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39. doi:10.1056/NEJMoa1507643. PMID:26412456.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123–35. doi:10.1056/NEJMoa1504627. PMID:26028407.
   PubMed Web of Science ®Google Scholar
• Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76. doi:10.1016/S0140-6736(16)32455-2. PMID:27939400.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20. doi:10.1016/S0140-6736(16)00561-4. PMID:26952546.
   PubMed Web of Science ®Google Scholar
• Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–22. doi:10.1016/S1470-2045(17)30065-7. PMID:28131785.
   PubMed Web of Science ®Google Scholar
• Ishihara D, Pop L, Takeshima T, Iyengar P, Hannan R. Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment. Cancer Immunology, Immunotherapy: CII. 2017;66(3):281–98. doi:10.1007/s00262-016-1914-6. PMID:27743027.
   PubMed Web of Science ®Google Scholar
• Crittenden M, Kohrt H, Levy R, Jones J, Camphausen K, Dicker A, Demaria S, Formenti S. Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol. 2015;25(1):54–64. doi:10.1016/j.semradonc.2014.07.003. PMID:25481267.
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74(19):5458–68. doi:10.1158/0008-5472.CAN-14-1258. PMID:25274032.
   PubMed Web of Science ®Google Scholar
• Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, Mansfield AS, Furutani KM, Olivier KR, Kwon ED. PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunol Res. 2015;3(6):610–9. doi:10.1158/2326-6066.CIR-14-0138. PMID:25701325.
   PubMed Web of Science ®Google Scholar
• Twyman-Saint\sVictor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–7. doi:10.1038/nature14292. PMID:25754329.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–95. doi:10.1172/JCI67313. PMID:24382348.
   PubMed Web of Science ®Google Scholar
• George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: A subgroup analysis of a randomized clinical trial. JAMA Oncol. 2016;2(9):1179–86. doi:10.1001/jamaoncol.2016.0775. PMID:27243803.
   PubMed Web of Science ®Google Scholar
• Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, Spektor A, Krishnan M, Ott PA, Balboni TA,et al. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy. Int J Radiat Oncol Biol Phys. 2017;98(2):344–51. doi:10.1016/j.ijrobp.2017.02.003. PMID:28463153.
   PubMed Web of Science ®Google Scholar
• Ahmed KA, Stallworth DG, Kim Y, Johnstone PA, Harrison LB, Caudell JJ, Yu HH, Etame AB, Weber JS, Gibney GT. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol. 2016;27(3):434–41. doi:10.1093/annonc/mdv622. PMID:26712903.
   PubMed Web of Science ®Google Scholar
• Williams NL, Wuthrick EJ, Kim H, Palmer JD, Garg S, Eldredge-Hindy H, Daskalakis C, Feeney KJ, Mastrangelo MJ, Kim LJ, et al. Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases. IJROBP. 2017;99(1):22–30.
   Google Scholar
• Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene. 2015;34(43):5411–7. doi:10.1038/onc.2015.5. PMID:25659583.
   PubMed Web of Science ®Google Scholar
• Qin R, Olson A, Singh B, Thomas S, Wolf S, Bhavsar NA, Hanks BA, Salama JK, Salama AK. Safety and efficacy of radiation therapy in advanced melanoma patients treated with ipilimumab. Int J Radiat Oncol Biol Phys. 2016;96(1):72–77. doi:10.1016/j.ijrobp.2016.04.017. PMID:27375168.
   PubMed Web of Science ®Google Scholar
• Boyer MJ, Gu L, Wang X, Kelsey CR, Yoo DS, Onaitis MW, Dunphy FR, Crawford J, Ready NE, Salama JK. Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. Lung Cancer. 2016;98:76–78. doi:10.1016/j.lungcan.2016.05.014. PMID:27393510.
   PubMed Web of Science ®Google Scholar
• Koller KM, Mackley HB, Liu J, Wagner H, Talamo G, Schell TD, Pameijer C, Neves RI, Anderson B, Kokolus KM, et al. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biol Ther. 2017;18(1):36–42. doi:10.1080/15384047.2016.1264543. PMID:27905824.
   PubMed Web of Science ®Google Scholar
• Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903. doi:10.1016/S1470-2045(17)30380-7. PMID:28551359.
   PubMed Web of Science ®Google Scholar
• Camphausen K, Moses MA, Menard C, Sproull M, Beecken WD, Folkman J, O'Reilly MS. Radiation abscopal antitumor effect is mediated through p53. Cancer Res. 2003;63(8):1990–3. PMID:12702593.
   PubMed Web of Science ®Google Scholar
• Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res. 2015;21(16):3727–39. doi:10.1158/1078-0432.CCR-14-2824. PMID:25869387.
   PubMed Web of Science ®Google Scholar
• Wattenberg MM, Fahim A, Ahmed MM, Hodge JW. Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy. Radiat Res. 2014;182(2):126–38. doi:10.1667/RR13374.1. PMID:24960415.
   PubMed Web of Science ®Google Scholar
• D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: A pooled analysis. J Clin Oncol. 2017;35(2):226–35. doi:10.1200/JCO.2016.67.9258. PMID:28056206.
   PubMed Web of Science ®Google Scholar
• Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol. 2015;26(9):1824–9. doi:10.1093/annonc/mdv182. PMID:25888611.
   PubMed Web of Science ®Google Scholar
• Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncol. 2016;2(10):1346–53. doi:10.1001/jamaoncol.2016.1051. PMID:27367787.
   PubMed Web of Science ®Google Scholar
• Madariaga ML, Kreisel D, Madsen JC. Organ-specific differences in achieving tolerance. Curr Opin Organ Transplant. 2015;20(4):392–9. doi:10.1097/MOT.0000000000000206. PMID:26147678.
   PubMed Web of Science ®Google Scholar
• Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–12. doi:10.1016/S1470-2045(14)70189-5. PMID:24831977.
   PubMed Web of Science ®Google Scholar
• Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, et al. Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T cells. Clin Cancer Res. 2017;23(6):1388–96. doi:10.1158/1078-0432.CCR-16-1432. PMID:27649551.
   PubMed Web of Science ®Google Scholar
• Hiniker SM, Reddy SA, Maecker HT, Subrahmanyam PB, Rosenberg-Hasson Y, Swetter SM, Saha S, Shura L, Knox SJ. A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. Int J Radiat Oncol Biol Phys. 2016;96(3):578–88. doi:10.1016/j.ijrobp.2016.07.005. PMID:27681753.
   PubMed Web of Science ®Google Scholar
• Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, Duret H, Yagita H, Johnstone RW, Smyth MJ, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer research. 2012;72(13):3163–74. doi:10.1158/0008-5472.CAN-12-0210. PMID:22570253.
   PubMed Web of Science ®Google Scholar
• Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, Whisnant JK, Milas L. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res: J Am Assoc Cancer Res. 2005;11(1):361–9.
   PubMed Web of Science ®Google Scholar
• Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res: J Am Assoc Cancer Res. 2009;15(17):5379–88. doi:10.1158/1078-0432.CCR-09-0265..
   PubMed Web of Science ®Google Scholar
• Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T,et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–95. doi:10.1182/blood-2009-02-206870. PMID:19349616.
   PubMed Web of Science ®Google Scholar
• Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 2012;83(4):1306–10. doi:10.1016/j.ijrobp.2011.09.049. PMID:22208977.
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618. doi:10.1038/ncomms15618. PMID:28598415.
   PubMed Web of Science ®Google Scholar
• Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70(3):847–52. doi:10.1016/j.ijrobp.2007.10.059. PMID:18262098.
   PubMed Web of Science ®Google Scholar
• Kim DWN, Medin PM, Timmerman RD. Emphasis on repair, not just avoidance of injury, facilitates prudent stereotactic ablative radiotherapy. Semin Radiat Oncol. 2017;27(4):378–92. doi:10.1016/j.semradonc.2017.04.007. PMID:28865521.
   PubMed Web of Science ®Google Scholar
• NIH. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. 2009; https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed August 2017.
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. doi:10.1016/j.ejca.2008.10.026. PMID:19097774.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20. doi:10.1158/1078-0432.CCR-09-1624. PMID:19934295.
   PubMed Web of Science ®Google Scholar